Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China
Table: Eisai -Q1 group results (IFRS)
Brief: Core Biomedicine Signs Exclusive Licensing Agreement With Eisai For Precision Oncology Programs
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
FDA Approves Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection As An Initiation Dose For Early Alzheimer's Disease
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug (updated)
Refile: FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Brief: FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's
Brief: Eisai Announces Strategic Investment Supported By The Uk Government’S Lsimf
Table: Eisai -2025/26 group results (IFRS)
Table: Eisai -2025/26 parent results
Roche gets second European approval for Alzheimer's test
Merck-Eisai combination cancer treatments miss main goals of late-stage trial (updated)
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Brief: Eisai: To Discontinue Administration Of Anticancer Agent EZH2 Inhibitor Tazverik Tablets 200 Mg Manufactured And Marketed In Japan
Brief: Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection